Sector News

Shire tops US reputation survey

June 19, 2015
Life sciences
Shire has been named the most reputable pharma company in the US in a new report from the Reputation Institute
 
The report used over 50,000 consumer rankings to measure the public’s perception of pharma firms based on seven dimensions: innovation, leadership, governance, citizenship, workplace, performance, and products and services. This was then translated into a ‘RepTrack’ score.
 
Shire came out on top­ with a score of 77.55. Sanofi, Bayer and Boerhinger Ingelheim were close behind with scores of 76, 75, and 74 respectively. The top five was rounded off by generics firm Perrigo, while AbbVie, Roche, Lilly, Novartis and Takeda filled out the top 10.
 
They key drivers behind a firm’s reputation score were whether it offers high quality products, whether it is an ethical and transparent company, and whether it is a good corporate citizen.
 
The survey also found that 60% of people’s decision to buy, recommend or invest in a company depends on its reputation, and that 54% of consumers would give reputable companies the benefit of a doubt in a crisis compared with only 20% for companies with a poor reputation.
 
A UK PatientView survey released this month also placed Sanofi highly for reputation among patients, with the French firm ranking first for its pricing strategies and innovative products.
 
But there were noticeable differences in the other results between the two surveys – for example, the rest of PatientView’s top five consisted of Pfizer, Roche, GSK and Novartis.
 
By George Underwood
 
 

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend